Atezolizumab
Atezolizumab is a humanized IgG1 monoclonal antibody therapy that blocks CD274 molecule, an immune checkpoint protein expressed on tumor cells and tumor-infiltrating immune cells.
Atezolizumab is a humanized IgG1 monoclonal antibody therapy that blocks CD274 molecule, an immune checkpoint protein expressed on tumor cells and tumor-infiltrating immune cells. Developed by Genentech/Roche and marketed as Tecentriq, it belongs to the class of immune checkpoint inhibitors used in cancer immunotherapy. By binding PD-L1, atezolizumab prevents its engagement of Programmed cell death 1 (PD-1) on T cells, releasing the inhibitory signal that suppresses cytotoxic T-cell responses within the tumor microenvironment and restoring antitumor immunity. Unlike agents directed at the receptor itself — such as nivolumab and pembrolizumab — atezolizumab targets the ligand, leaving PD-1/PD-L2 interactions intact. It is approved across several solid tumors, including non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), triple-negative breast cancer, and urothelial carcinoma, and is administered intravenously as well as in a subcutaneous formulation.
In practice, atezolizumab is used both as monotherapy and, more commonly, within combination regimens. Its most established combination pairs it with bevacizumab, an anti-VEGF antibody, as first-line treatment for unresectable HCC — a regimen that displaced sorafenib as standard of care and provides the rationale for pairing checkpoint blockade with antiangiogenic therapy, since VEGF signaling itself contributes to an immunosuppressive tumor microenvironment. It is also combined with cytotoxic chemotherapy such as carboplatin and paclitaxel in lung and breast cancer. Related soluble mediators, including TGF-β1, Interleukin-6 (IL-6), and interferon gamma, together with tumor PD-L1 expression and circulating markers such as soluble PD-L1 and cell-free tumor DNA, are actively investigated as determinants of response. As with other checkpoint inhibitors, treatment carries a characteristic spectrum of immune-related adverse events — among them myocarditis, myositis, encephalitis, and endocrinopathies such as fulminant type 1 diabetes — that shape patient selection and monitoring, particularly in patients with underlying liver disease.
Where the papers sit
27 papers from the last 6 months study atezolizumab directly · updated from PubMed 16 Nov 2026
Study type 6 clinical trials · 12 observational · 2 human data · 2 preclinical · 5 unclassified
Themes 3 themes
-
Atezolizumab-Bevacizumab in HCC
Atezolizumab plus bevacizumab is moving from trial evidence into real-world treatment pathways for unresectable HCC. Response and survival are being refined through AFP, DCP, lymphocyte-to-monocyte ratio, body composition and cardiovascular-risk measures. Studies also address proteinuria, portosystemic shunting and locoregional therapies after inadequate response. Comparison with durvalumab plus tremelimumab and uncertainty about second-line sequencing remain open questions.
13 papers · 48.1%
-
PD-L1 Combination Immunotherapy
PD-L1 blockade is moving toward intensified and targeted combinations rather than isolated treatment. CTLA-4 inhibition, VEGF blockade, CD27 agonism, radiation, nanoparticles and engineered delivery systems recur as strategies to improve tumor immunogenicity. Response appears shaped by pre-existing immunity and dynamic myeloid remodeling. Immune-related toxicity, including encephalitis and demyelination, remains an important limit.
8 papers · 29.6%
-
Atezolizumab in Lung Cancer
Atezolizumab treatment in lung cancer is expanding through alternative administration, radiation combinations and biomarker-guided selection. Tiragolumab intensification in PD-L1-high disease and stereotactic radiation seek better control, while gut microbiota and immune-nutritional status are emerging outcome markers. Real-world comparisons with durvalumab address survival, toxicity and cost across small-cell and non-small-cell disease. The benefit of these additions remains variable and requires further validation.
6 papers · 22.2%
Papers
The 27 papers from the last 6 months that study atezolizumab directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Atezolizumab-Bevacizumab in HCC (13)
- Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092). Future oncology (London, England) · 21 Oct 2026 PMID 42902603
- Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores. Liver international : official journal of the International Association for the Study of the Liver · 7 Oct 2026 PMID 42839680
- Clinical Determinants Influencing First-line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma in Japan. Anticancer research · 1 Oct 2026 PMID 42823164
- Antiproteinuric Effect of SGLT2 Inhibitors in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Anticancer research · 31 Aug 2026 PMID 42674726
- Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma. Anticancer research · 31 Aug 2026 PMID 42674706
- Early LMR Dynamics and AFP Status in Advanced HCC Treated With Atezolizumab/Bevacizumab. Anticancer research · 31 Aug 2026 PMID 42674689
- Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy. Clinical nutrition ESPEN · 20 Aug 2026 PMID 42624401
- Real-world evidence for atezolizumab with bevacizumab for unresectable hepatocellular carcinoma: a multicentre UK Midlands cohort. BMC cancer · 20 Jul 2026 PMID 42477572
- Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC. Liver international : official journal of the International Association for the Study of the Liver · 20 Jul 2026 PMID 42477505
- Safety of Immune-Targeted Therapy in Patients with Hepatocellular Carcinoma in the Real-World. Journal of gastrointestinal cancer · 16 Jul 2026 PMID 42461453
- Balloon-occluded Alternative Infusion of Fragmented Gelatin Particles of TACE for Hepatocellular Carcinoma Refractory to Atezolizumab-Bevacizumab. Anticancer research · 29 Jun 2026 PMID 42373279
- Second-Line Practices in the Era of Immunotherapy in HCC: The CHIEF Cohort. JHEP reports : innovation in hepatology · 11 Jun 2026 PMID 42276189
- Diagnostic Pathways and Outcomes of First-Line Atezolizumab plus Bevacizumab in Patients with Locoregional Therapy-Ineligible Hepatocellular Carcinoma at Initial Diagnosis. Oncology · 29 May 2026 PMID 42213615
PD-L1 Combination Immunotherapy (8)
- Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade. Journal for immunotherapy of cancer · 26 Aug 2026 PMID 42648751
- Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States. Human vaccines & immunotherapeutics · 22 Aug 2026 PMID 42630013
- A Randomized Phase II Study of Combination Atezolizumab and Varlilumab (CDX-1127) with or without Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jun 2026 PMID 42377085
- MT3-KN035 Nanoparticles Based on PD-L1 Nanobodies Allow for Multiple Drug Conjugations that Promote Chemo- and Immunosynergistic Therapies. ACS biomaterials science & engineering · 23 Jun 2026 PMID 42334414
- Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial. The lancet. Gastroenterology & hepatology · 22 Jun 2026 PMID 42330996
- Synchronous Late-Onset of Limbic Encephalitis and Tumefactive Demyelinating Lesion After the End of Immunotherapy. Clinical nuclear medicine · 16 Jun 2026 PMID 42302392
- Targeted immunotherapy and tumor immunogenicity in liver transplant recipients: A study on lenvatinib and PD-L1 inhibition. Pakistan journal of pharmaceutical sciences · 9 Jun 2026 PMID 42262196
- Focused acoustic vortex-mediated targeted aggregation of engineered bacteria for in situ antibody production to enhance immunotherapy. Acta biomaterialia · 30 May 2026 PMID 42217659
Atezolizumab in Lung Cancer (6)
- Baseline Gut Microbiota Composition Links Immune-nutritional Status to Clinical Outcomes in Non-small Cell Lung Cancer Treated With Atezolizumab-based Immunotherapy: A Multicenter Prospective Study. Anticancer research · 1 Oct 2026 PMID 42823161
- Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet (London, England) · 6 Sept 2026 PMID 42702214
- Atezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan: a real-world comparative analysis of costs and clinical outcomes. Japanese journal of clinical oncology · 16 Aug 2026 PMID 42604595
- SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 27 Jul 2026 PMID 42507968
- Feasibility of Reconstructing Survival Outcomes from Unstructured Electronic Medical Records under Japan's Next-Generation Medical Infrastructure Act: A Historical Cohort Study of Atezolizumab in Non-small Cell Lung Cancer. Drugs - real world outcomes · 23 Jul 2026 PMID 42489799
- Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies. Lung cancer (Amsterdam, Netherlands) · 29 May 2026 PMID 42214243
By study type
Clinical trials (6)
- Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet (London, England) · 6 Sept 2026 PMID 42702214
- Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade. Journal for immunotherapy of cancer · 26 Aug 2026 PMID 42648751
- SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 27 Jul 2026 PMID 42507968
- A Randomized Phase II Study of Combination Atezolizumab and Varlilumab (CDX-1127) with or without Cobimetinib in Previously Treated Unresectable Biliary Tract Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research · 30 Jun 2026 PMID 42377085
- Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2-3 trial. The lancet. Gastroenterology & hepatology · 22 Jun 2026 PMID 42330996
- Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies. Lung cancer (Amsterdam, Netherlands) · 29 May 2026 PMID 42214243
Observational studies and case reports (12)
- Stratifying Cardiovascular Risk in Patients With HCC Receiving Atezolizumab/Bevacizumab: A Comparison of ESC and CARDIOSOR Scores. Liver international : official journal of the International Association for the Study of the Liver · 7 Oct 2026 PMID 42839680
- Clinical Determinants Influencing First-line Immune Checkpoint Inhibitor Selection for Unresectable Hepatocellular Carcinoma in Japan. Anticancer research · 1 Oct 2026 PMID 42823164
- Baseline Gut Microbiota Composition Links Immune-nutritional Status to Clinical Outcomes in Non-small Cell Lung Cancer Treated With Atezolizumab-based Immunotherapy: A Multicenter Prospective Study. Anticancer research · 1 Oct 2026 PMID 42823161
- Antiproteinuric Effect of SGLT2 Inhibitors in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Anticancer research · 31 Aug 2026 PMID 42674726
- Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma. Anticancer research · 31 Aug 2026 PMID 42674706
- Early LMR Dynamics and AFP Status in Advanced HCC Treated With Atezolizumab/Bevacizumab. Anticancer research · 31 Aug 2026 PMID 42674689
- Concurrent low skeletal muscle mass and fat area may predict poor survival in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab therapy. Clinical nutrition ESPEN · 20 Aug 2026 PMID 42624401
- Atezolizumab vs durvalumab for extensive-stage small cell lung cancer in Japan: a real-world comparative analysis of costs and clinical outcomes. Japanese journal of clinical oncology · 16 Aug 2026 PMID 42604595
- Baseline DCP May Modify Response to Atezolizumab-Bevacizumab Versus Durvalumab-Tremelimumab in Unresectable HCC. Liver international : official journal of the International Association for the Study of the Liver · 20 Jul 2026 PMID 42477505
- Balloon-occluded Alternative Infusion of Fragmented Gelatin Particles of TACE for Hepatocellular Carcinoma Refractory to Atezolizumab-Bevacizumab. Anticancer research · 29 Jun 2026 PMID 42373279
- Synchronous Late-Onset of Limbic Encephalitis and Tumefactive Demyelinating Lesion After the End of Immunotherapy. Clinical nuclear medicine · 16 Jun 2026 PMID 42302392
- Targeted immunotherapy and tumor immunogenicity in liver transplant recipients: A study on lenvatinib and PD-L1 inhibition. Pakistan journal of pharmaceutical sciences · 9 Jun 2026 PMID 42262196
Human data, design not indexed (2)
- Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States. Human vaccines & immunotherapeutics · 22 Aug 2026 PMID 42630013
- Safety of Immune-Targeted Therapy in Patients with Hepatocellular Carcinoma in the Real-World. Journal of gastrointestinal cancer · 16 Jul 2026 PMID 42461453
Preclinical: animal, cell and lab studies (2)
- MT3-KN035 Nanoparticles Based on PD-L1 Nanobodies Allow for Multiple Drug Conjugations that Promote Chemo- and Immunosynergistic Therapies. ACS biomaterials science & engineering · 23 Jun 2026 PMID 42334414
- Focused acoustic vortex-mediated targeted aggregation of engineered bacteria for in situ antibody production to enhance immunotherapy. Acta biomaterialia · 30 May 2026 PMID 42217659
Unclassified: not yet indexed with MeSH (5)
- Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092). Future oncology (London, England) · 21 Oct 2026 PMID 42902603
- Feasibility of Reconstructing Survival Outcomes from Unstructured Electronic Medical Records under Japan's Next-Generation Medical Infrastructure Act: A Historical Cohort Study of Atezolizumab in Non-small Cell Lung Cancer. Drugs - real world outcomes · 23 Jul 2026 PMID 42489799
- Real-world evidence for atezolizumab with bevacizumab for unresectable hepatocellular carcinoma: a multicentre UK Midlands cohort. BMC cancer · 20 Jul 2026 PMID 42477572
- Second-Line Practices in the Era of Immunotherapy in HCC: The CHIEF Cohort. JHEP reports : innovation in hepatology · 11 Jun 2026 PMID 42276189
- Diagnostic Pathways and Outcomes of First-Line Atezolizumab plus Bevacizumab in Patients with Locoregional Therapy-Ineligible Hepatocellular Carcinoma at Initial Diagnosis. Oncology · 29 May 2026 PMID 42213615
Written from 27 PubMed abstracts, each one listed by PMID above. Published: 2026-06-13. Last written: 2026-09-02 by GPT. Reviewed by a human editor on 2026-07-23. Drafted by language models from published abstracts; not medical advice.